HSV-MARKERS AND THE EPIDEMIOLOGY OF CERVICAL CANCER

本提案中描述的实验方案旨在 人单纯疱疹病毒（HSV）感染的定量标志物 已经参加宫颈癌流行病学研究的人群 癌 患者和对照组是参与 题为“宫颈癌病例对照研究”的研究。 患者和 对照组是参与题为“病例对照”研究的个体 宫颈癌的侵袭性研究”，由美国国家癌症研究所资助， 研究所，目前正在进行中的科罗拉多大学学院， 药 作为一项合作奋进，我们计划利用这些血液 单纯疱疹病毒感染的证据， 确定它们对病毒抗原的免疫反应程度。 的 具体目标是：1）定量淋巴细胞增殖反应 灭活的HSV-1和HSV-2病毒和型特异性糖蛋白（gC）; 2)为了检查循环淋巴细胞中是否存在病毒DNA， 测量DNA的量，并通过使用特异性探针确定是否 病毒是1型还是2型; 3）通过酶联测定 免疫测定，血清抗疱疹病毒总抗原抗体水平 型特异性糖蛋白gC; 4）利用这些技术 在已知HSV感染的人中， 一项正在进行的宫颈癌病例和对照研究。 的 实验室生成的定量数据将首先使用 在体外实验中已知HSV感染的细胞系。 接下来，白色细胞 材料将从已知感染HSV-1的人获得， HSV-2来自丹佛健康的性传播疾病诊所， 医院的 这将有助于验证调查结果，并帮助建立 程序的敏感性和特异性。 下一个，校长 本提案协作部分的重点是白色细胞样本 将从已经参与病例对照的人员中进行分析 宫颈癌的治疗 这将允许对实验室进行检查 HSV经历信息与流行病学信息 与其他潜在病因学和混杂因素相关，例如 吸烟、营养状况、性和传染病史，以及 避孕和激素使用模式。

The experimental program described in this proposal is designed to quantitate markers of Herpes simplex virus (HSV) infection in a human population already participating in an epidemiological study of cervical cancer. The patients and control groups are individuals involved in the study entitled "Case-control study of cervical cancer". The patients and control groups are individuals involved in the study entitled "Case-control study of invasive cervical cancer", funded by the National Cancer Institute, at present underway at the University of Colorado School of Medicine. As a collaborative endeavor, we plan to utilize blood from these individuals to assay for evidence of Herpes simplex virus infection and determine the extent of their immune responsiveness to viral antigens. The specific aims are: 1) To quantitate lymphocyte proliferation in response to inactivated HSV-1 and HSV-2 virus and a type specific glycoprotein (gC); 2) To examine circulating lymphocytes for the presence of viral DNA, measure the amount of DNA, and by use of specific probes establish whether the virus is type 1 or type 2; 3) To determine by an enzyme linked immunoassay, the serum antibody levels against total herpes virus antigens and the type specific glycoprotein gC; and 4) To utilize these techniques in persons with known HSV infections, and to incorporate these techniques into an on-going study of cervical cancer cases and controls. The quantitative data generated by the laboratory will first be developed using known HSV infected cell lines in in vitro experiments. Next, white cell material will be obtained from persons known to be infected with HSV-1 and HSV-2 from the sexually transmitted diseases clinic of Denver Health and Hospitals. This will serve to validate the findings, and help establish the sensitivity and specificity of the procedures. Next, and the principal focus of the collaborative portion of this proposal, white cell samples will be analyzed from persons already participating in the case-control study of cervical cancer. This will allow examination of the laboratory information on HSV experience simultaneously with epidemiologic information relevant to other potential etiologic and confounding factors, such as smoking, nutritional status, sexual and infectious disease history, and contraceptive and hormone useage patterns.